Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab improves the quality of response in patients with previously untreated chronic lymphocytic leukemia.

被引：0
|
作者：
Weiss, MA [1 ]
Lamanna, N [1 ]
Gencarelli, A [1 ]
Scheinberg, DA [1 ]
Maslak, PG [1 ]
Horgan, D [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5019
引用
收藏
页码：365B / 365B
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL)
    Hornberger, J. C.
    Reyes, C. M.
    Shewade, A.
    Friedmann, M.
    Chan, L.
    Gutierrez, H.
    Satram-Hoang, S.
    Lerner, S.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
    Nicole Lamanna
    Mark A. Weiss
    Current Hematologic Malignancy Reports, 2009, 4 (4) : 185 - 186
  • [23] Result of an open-label, pilot study of pentostatin, rituximab, and cyclophosphamide, in the treatment of patients with previously untreated chronic lymphocytic leukemia.
    Reynolds, C
    Di Bella, NJ
    Drapkin, R
    Murali, M
    Boehm, KA
    Asmar, L
    BLOOD, 2003, 102 (11) : 357B - 357B
  • [24] Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia.
    Weiss, MA
    Lamanna, N
    Kalaycio, M
    Jurcic, J
    Maslak, P
    Gencarelli, A
    Scheinberg, D
    Horgan, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 574S - 574S
  • [25] Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia.
    Lamanna, N
    Kalaycio, M
    Maslak, P
    Heaney, ML
    Brentjens, R
    Jurcic, J
    Biederman, E
    Gencarelli, AN
    Panageas, KS
    Scheinberg, DA
    Weiss, MA
    BLOOD, 2005, 106 (11) : 601A - 602A
  • [26] RESULTS OF A PHASE III TRIAL OF FLUDARABINE, CICLOPHOSPHAMIDE AND RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS (P) WITH CHRONIC LYMPHOCYTIC LEUKEMIA. SECOND INTERIM ANALYSIS
    Riveros, D.
    Bezares, R.
    Stemmelin, G.
    Milone, G.
    Kusminsky, G.
    Cerutti, I.
    Pantano, J.
    Garcia, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 243 - 243
  • [27] Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Manero, GG
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Albitar, M
    Lerner, S
    Kantarjian, H
    Keating, M
    BLOOD, 2001, 98 (11) : 633A - 633A
  • [28] Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).
    Tarhini, Ahmad A.
    Land, S.
    Meisner, D.
    Pietragallo, L.
    Sulecki, M.
    Lim, F.
    Kiefer, Gauri J.
    Pinkerton, R.
    Obsom, J.
    Sukaly, S.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2006, 108 (11) : 805A - 805A
  • [29] Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia
    Shehata, Medhat
    Demirtas, Dita
    Tauber, Stefanie
    Schnabl, Susanne
    Bilban, Martin
    Hilgarth, Martin
    Wagner, Oswald
    Fonatsch, Christa
    Schwarzinger, Ilse
    Hopfinger, Georg
    Eigenberger, Karin
    Skrabs, Cathrin
    Heintel, Daniel
    Porpaczy, Edit Anna
    Vanura, Katrina
    Stilgenbauer, Stephan
    Hallek, Michael
    Schwarzmeier, Josef D.
    Hubmann, Rainer
    Gaiger, Alexander
    Jaeger, Ulrich
    BLOOD, 2008, 112 (11) : 573 - 573
  • [30] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzani, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John Francis
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Fischer, Kirsten
    BLOOD, 2008, 112 (11) : 125 - 125
12345